

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.co

Carlyle likely to invest \$100 M in BDR Pharma

14 August 2018 | News

BDR Pharma which manufactures drugs across therapy areas such as oncology, critical care and gynaecology is looking to expand its business into new geographies



Private equity firm Carlyle is in talks with promoters of Mumbai-based BDR Pharma to invest \$100 million in the drug company, the funding for which is expected to be used in expanding the company's operations.

BDR Pharma which manufactures drugs across therapy areas such as oncology, critical care and gynaecology is looking to expand its business into new geographies. The company will be going for aggressive expansion by making investments worth \$70million in developing the infrastructure of the company.

BDR clocked Rs 550-600 crore in revenue and around Rs 120 crore in FY18 EBITDA, BDR is being valued at \$700 million. India's pharma market though reeling under pressures of price cuts has seen a nearly 12% growth showing signs of recovery. For PE players like Carlyle, it is this growth in the Indian pharma market that holds the attraction.